TuHURA Biosciences (NASDAQ:HURA) Releases Earnings Results

TuHURA Biosciences (NASDAQ:HURA) announced its quarterly earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01, FiscalAI reports.

TuHURA Biosciences Price Performance

NASDAQ HURA traded up $0.17 on Friday, reaching $2.47. The company had a trading volume of 317,089 shares, compared to its average volume of 235,478. The firm has a market cap of $157.29 million, a price-to-earnings ratio of -4.05 and a beta of -0.01. TuHURA Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $3.43. The business has a 50 day moving average of $2.28 and a two-hundred day moving average of $2.00.

Analysts Set New Price Targets

A number of brokerages recently weighed in on HURA. Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, May 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Friday, July 17th. Citigroup began coverage on TuHURA Biosciences in a report on Monday, April 27th. They set an “outperform” rating on the stock. Finally, Citizens Jmp began coverage on TuHURA Biosciences in a research note on Monday, April 27th. They issued a “market outperform” rating and a $9.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $9.00.

Institutional Investors Weigh In On TuHURA Biosciences

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of TuHURA Biosciences by 1.6% during the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock worth $5,629,000 after acquiring an additional 35,426 shares during the last quarter. Geode Capital Management LLC boosted its holdings in TuHURA Biosciences by 6.4% in the fourth quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock valued at $501,000 after acquiring an additional 39,710 shares during the last quarter. State Street Corp boosted its holdings in TuHURA Biosciences by 4.9% in the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock valued at $219,000 after acquiring an additional 13,594 shares during the last quarter. Deutsche Bank AG increased its position in TuHURA Biosciences by 209.8% during the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after purchasing an additional 54,051 shares during the period. Finally, Barclays PLC increased its position in TuHURA Biosciences by 42.6% during the 4th quarter. Barclays PLC now owns 52,615 shares of the company’s stock valued at $40,000 after purchasing an additional 15,725 shares during the period. Institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.